Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report. [PDF]
Shimada H +4 more
europepmc +1 more source
A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. [PDF]
Harikul W +6 more
europepmc +1 more source
Advancing Strategies to Optimise the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) study: rationale and design for a sequential, repeated crossover trial. [PDF]
Stallings EG +11 more
europepmc +1 more source
Comparison of Ondansetron and Cyclizine for the Management of Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis. [PDF]
Hamid S, Bahaj B, Sajhad ZU.
europepmc +1 more source
Incidence and Risk Factors of Delayed Chemotherapy-Induced Nausea and Vomiting Among Adult Patients: A Cross-Sectional Study. [PDF]
Zheng M +9 more
europepmc +1 more source
Prevalence and risk factors for nausea and vomiting in breast cancer patients undergoing chemotherapy. [PDF]
Feng Y, Wei L, Zou Q, Lei X, Yang X.
europepmc +1 more source
PACU Outcomes Across Anesthesiology Resident Training Levels: A Retrospective Cohort Study. [PDF]
Jefferies HB +3 more
europepmc +1 more source
Efficacy of intravenous amisulpride and ondansetron in preventing post-operative nausea and vomiting in patients undergoing craniotomy for supratentorial tumour surgery: A randomised non-inferiority trial. [PDF]
Ravindranath S +4 more
europepmc +1 more source
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Platinum-Based Delayed-Phase Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis. [PDF]
Gong W +5 more
europepmc +1 more source
Influence of Hypnosis and Acupuncture on Perioperative Complications. [PDF]
Markovič-Božič J +9 more
europepmc +1 more source

